Celularity Inc.
Celularity is a clinical and commercial stage biotechnology company focused on cellular and regenerative medicine, specializing in off-the-shelf placental-derived allogeneic cell therapies and biomaterial products aimed at addressing serious unmet medical needs.
Investor website: https://celularity.com/
We don’t have processed documents for Celularity Inc. yet, so the AI assistant isn’t available on this page.
About
Celularity is a clinical and commercial stage biotechnology company focused on cellular and regenerative medicine, specializing in off-the-shelf placental-derived allogeneic cell therapies and biomaterial products aimed at addressing serious unmet medical needs. The company believes in leveraging the unique biology of the placenta to develop effective, accessible, and affordable therapeutics.
Verified company data
- Cash position
- $37.2 million
- Shares outstanding
- 217828609
- Projects
- ["Advanced Biomaterials Pipeline\n| Advanced Biomaterials | Indication | Discovery | Regulatory | Commercialization |\n| --- | --- | --- | --- | --- |\n| **Amniotic Membrane Allograft** | Wound Care | <br>361 HCT/P |\n| **Tri-Layer Amniotic Membrane Allograft** | Wound Care | <br>361 HCT/P |\n| **Tri-Layer Amniotic Membrane Allograft** | Ocular Protective Cover | <br>361 HCT/P |\n| **Amniotic Membrane Allograft** | Wound Care | <br>361 HCT/P |\n| **Tri-Layer Amniotic Membrane Allograft** | Wound Care | <br>361 HCT/P |\n| **Placental Connective Tissue Matrix** | Wound Care | <br>361 HCT/P |\n| **Tri-Layer Amniotic Membrane Allograft** | Wound Care | <br>361 HCT/P |\n| **Celularity Tendon Wrap (CTW)** | Surgical Tendon Management | <br>Expected 510(k) filing |\n| **FUSE Bone Void**<br>**Filler** | Orthopedics / Bone, Spine, Dental | <br>Expected 510(k) filing |\n| **Celularity Placental Matrix (CPM)** | Soft Tissue Management | <br>Expected 510(k) filing |"]
- Leadership
- Robert J. Hariri, M.D., Ph.D. (Chairperson, Founder & CEO), Anna Gosiewska, Ph.D. (R&D, Degenerative Diseases), Sharmila Koppisetti, M.D. (Clinical Development Immunology & Drug Safety), Tim Wilk (Technical Operations), Bradley Glover, Ph.D. (Executive Vice President and Chief Technology Officer, Over 20 years of experience in pharmaceutical industry, previously held executive roles at Kite Pharma, Genentech, and Roche.), Andrew L. Pecora, M.D., F.A.C.P., C.P.E. (President, Renowned clinician and scientist with over 25 years of experience in biotechnology and healthcare.)
Verified data last updated: